Biogen Inc (BIIB)

$193.45 +2.07 (1.08%)
Market Cap 28.56B
Revenue (ttm) 9.89B
Net Income (ttm) 1.29B
EPS (ttm) N/A
PE Ratio 12.08
Forward PE 13.37
Profit Margin 13.07%
Debt to Equity Ratio 0.34
Volume 931,500
Avg Vol 1,123,280
Day's Range N/A - N/A
Shares Out 147.64M
Stochastic %K 84%
Beta 0.19
Analysts Strong Sell
Price Target $217.72

Company Profile

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referenc...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 617 679 2000
Address:
225 Binney Street, Cambridge, United States
AStrokeOfLuck
AStrokeOfLuck May. 8 at 8:12 AM
$BIIB
0 · Reply
TwongStocks
TwongStocks May. 7 at 6:03 PM
$APLS Equity Corporate Actions Alert #2026 - 310 Information Regarding the Tender Offer of Apellis Pharmaceuticals, Inc. (APLS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-310 The tender offer by Biogen Inc. $BIIB to acquire all of the outstanding common stock of Apellis Pharmaceuticals, Inc. $APLS is scheduled to expire at 11:59 p.m. ET, on May 13, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 14, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 13, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 14th) and will be suspended effective May 15, 2026. APLS shareholders will get $41.00 per share plus a non-transferable contingent value right (CVR).
0 · Reply
CapitalMonk
CapitalMonk May. 5 at 3:56 AM
$BIIB Price: $187.21 (+0.08%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.63% RSI: 58.1 | Momentum: Moderate Volume: -49.9% vs avg Volatility: 2.30% Support: $170.43 | Resistance: $195.98 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
JFais
JFais Apr. 30 at 7:58 PM
$OMER (L) When they did the zaltenibart deal in October, it gave them a lifeline as no one knew if narsoplimab would get approved in TA-TMA Also, bear commentary= slow launch out of the gate (so far, formulary wins exceeding expectations) I imagine $NVO would love to take Yartemlea into expansion indications (ARDS & other endothelial injury-related disorders), also continue building out its nephrology presence... *Though $BIIB could be another interested party after digesting $APLS
2 · Reply
OMillionaires
OMillionaires Apr. 30 at 10:50 AM
$BIIB PT raised to $260 from $246 at Guggenheim - keeps Buy rating
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 3:55 AM
$BIIB Share Price: $194.59 Contract Selected: May 22, 2026 $195 Calls Buy Zone: $4.50 – $5.57 Target Zone: $8.02 – $9.80 Potential Upside: 68% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
EarningsLens_ai
EarningsLens_ai Apr. 29 at 1:22 PM
$BIIB blew past estimates but the story underneath is more complicated. Cash flow nearly tripled, which sounds great until you see cost of revenue growing 3x faster than revenue and debt up 38% YoY to $6.29B. Q2 working capital reversal is the thing to watch.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 10:16 AM
$BIIB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $2.17 up 31.52% YoY • Reported revenue of $2.48B up 1.93% YoY • Biogen updated full year 2026 Non-GAAP diluted EPS guidance to $14.25 to $15.25, reflecting an approximately $1.00 impact from acquired IPR&D charges, and expects total revenue to decline by a mid-single digit percentage.
0 · Reply
trichomy
trichomy Apr. 27 at 2:39 PM
$INMB $LEMB $BIIB Let's go InmuneBio!! https://claude.ai/public/artifacts/3dd6649c-e7bf-4f60-9771-28a79622d962 INMB INMB INMB
0 · Reply
Latest News on BIIB
Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA

2026-05-08T09:20:59.000Z - 1 day ago

Eisai, Biogen announce FDA extension of review period for lecanemab-irmb sBLA

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

May 8, 2026, 2:30 AM EDT - 2 days ago

Update on FDA Priority Review of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection as a Starting Dose for Early Alzheimer's Disease

Remitly Global to replace Apellis in S&P 600 at open on 5/14

2026-05-07T22:27:46.000Z - 2 days ago

Remitly Global to replace Apellis in S&P 600 at open on 5/14

APLS RELY

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

May 7, 2026, 6:01 PM EDT - 2 days ago

Bright Horizons Family Solutions and Remitly Global Set to Join S&P SmallCap 600

APLS BFAM RELY TPH

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

May 7, 2026, 4:01 PM EDT - 2 days ago

Stoke Therapeutics Announces First Quarter 2026 Financial Results and Provides Business Updates

STOK

Biogen upgraded to Buy from Hold at Freedom Broker

2026-05-01T14:53:17.000Z - 8 days ago

Biogen upgraded to Buy from Hold at Freedom Broker

Biogen price target raised to $190 from $189 at Truist

2026-05-01T12:48:48.000Z - 8 days ago

Biogen price target raised to $190 from $189 at Truist

Biogen price target raised to $200 from $190 at Citi

2026-05-01T10:17:29.000Z - 8 days ago

Biogen price target raised to $200 from $190 at Citi

Biogen price target raised to $206 from $200 at Morgan Stanley

2026-04-30T17:54:40.000Z - 9 days ago

Biogen price target raised to $206 from $200 at Morgan Stanley

Biogen price target raised to $222 from $213 at RBC Capital

2026-04-30T14:06:05.000Z - 9 days ago

Biogen price target raised to $222 from $213 at RBC Capital

Biogen price target raised to $196 from $191 at Wedbush

2026-04-30T11:55:25.000Z - 9 days ago

Biogen price target raised to $196 from $191 at Wedbush

Biogen price target raised to $260 from $246 at Guggenheim

2026-04-30T11:08:22.000Z - 9 days ago

Biogen price target raised to $260 from $246 at Guggenheim

APLS

Biogen price target raised to $203 from $200 at BofA

2026-04-29T19:05:57.000Z - 10 days ago

Biogen price target raised to $203 from $200 at BofA

Biogen Earnings Call Transcript: Q1 2026

Apr 29, 2026, 8:00 AM EDT - 10 days ago

Biogen Earnings Call Transcript: Q1 2026

Biogen Lowers 2026 Earnings Outlook

Apr 29, 2026, 7:02 AM EDT - 10 days ago

Biogen Lowers 2026 Earnings Outlook

Biogen lowers FY26 adjusted EPS view to $14.25-$15.25, consensus $15.55

2026-04-29T10:25:04.000Z - 10 days ago

Biogen lowers FY26 adjusted EPS view to $14.25-$15.25, consensus $15.55

Biogen reports Q1 adjusted EPS $3.57, consensus $2.95

2026-04-29T10:14:27.000Z - 10 days ago

Biogen reports Q1 adjusted EPS $3.57, consensus $2.95

APLS

Biogen cuts annual profit forecast on acquisition-related charges

Apr 29, 2026, 6:07 AM EDT - 10 days ago

Biogen cuts annual profit forecast on acquisition-related charges

Biogen price target raised to $200 from $197 at BofA

2026-04-24T19:10:18.000Z - 15 days ago

Biogen price target raised to $200 from $197 at BofA

Biogen upgraded to Buy from Neutral at UBS

2026-04-22T09:05:14.000Z - 17 days ago

Biogen upgraded to Buy from Neutral at UBS

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Apr 20, 2026, 9:02 AM EDT - 19 days ago

Biogen buys China rights to immune disease drug in up to $850 million deal with TJ Biopharma

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

Apr 20, 2026, 7:30 AM EDT - 19 days ago

Biogen Enters into Agreement with TJ Biopharma for Felzartamab Assets in the Greater China Region

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

Apr 18, 2026, 9:00 AM EDT - 21 days ago

These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.

LLY

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Apr 7, 2026, 6:00 AM EDT - 4 weeks ago

Alloy Therapeutics Enters into Multi-Target Collaboration and License Agreement with Biogen for Use of Alloy's AntiClastic™ ASO Platform

Why This Pharma Stock More Than Doubled Today

Mar 31, 2026, 9:41 AM EDT - 5 weeks ago

Why This Pharma Stock More Than Doubled Today

APLS

Biogen Transcript: M&A announcement

Mar 31, 2026, 8:30 AM EDT - 5 weeks ago

Biogen Transcript: M&A announcement

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

Mar 31, 2026, 8:07 AM EDT - 5 weeks ago

Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases

APLS

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

Mar 31, 2026, 7:44 AM EDT - 5 weeks ago

Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion

APLS

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

Mar 31, 2026, 7:05 AM EDT - 5 weeks ago

Biogen to buy Apellis Pharmaceuticals for $5.6 billion

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

Mar 31, 2026, 6:59 AM EDT - 5 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology.

APLS

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

Mar 31, 2026, 6:59 AM EDT - 5 weeks ago

Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

APLS

US FDA approves higher-dose of Biogen's genetic disorder drug

Mar 30, 2026, 7:36 AM EDT - 5 weeks ago

US FDA approves higher-dose of Biogen's genetic disorder drug

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Mar 30, 2026, 7:30 AM EDT - 5 weeks ago

FDA Approves New High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

IONS

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Mar 28, 2026, 3:00 PM EDT - 6 weeks ago

Biogen Announces Second Positive Phase 2 Litifilimab Trial in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting, Showing a Significant Reduction in Skin Disease Activity

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Mar 25, 2026, 8:00 AM EDT - 6 weeks ago

Alteogen Enters into a License Agreement with Biogen for Development and Commercialization of Hybrozyme™-Based Subcutaneous Biologics

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Mar 20, 2026, 12:05 PM EDT - 7 weeks ago

Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Mar 19, 2026, 7:30 AM EDT - 7 weeks ago

Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Mar 18, 2026, 9:30 AM EDT - 7 weeks ago

Biogen Transcript: Stifel 2026 Virtual CNS Forum

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Mar 11, 2026, 8:00 AM EDT - 2 months ago

Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy

Biogen Transcript: Leerink Global Healthcare Conference 2026

Mar 10, 2026, 1:00 PM EDT - 2 months ago

Biogen Transcript: Leerink Global Healthcare Conference 2026

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

Mar 5, 2026, 7:30 AM EST - 2 months ago

Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences

IONS

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

Mar 4, 2026, 5:06 PM EST - 2 months ago

The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome

STOK

Biogen Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 9:10 AM EST - 2 months ago

Biogen Transcript: TD Cowen 46th Annual Health Care Conference

Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Feb 13, 2026, 10:30 AM EST - 3 months ago

Biogen Transcript: Piper Sandler Virtual Novel Targets in Immunology Symposium

Biogen Announces Board Chair Transition

Feb 11, 2026, 5:00 PM EST - 3 months ago

Biogen Announces Board Chair Transition

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Feb 6, 2026, 8:59 AM EST - 3 months ago

Biogen 4Q Revenue Down as Multiple Sclerosis Sales Slide

Biogen Earnings Call Transcript: Q4 2025

Feb 6, 2026, 8:30 AM EST - 3 months ago

Biogen Earnings Call Transcript: Q4 2025

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Feb 6, 2026, 7:35 AM EST - 3 months ago

Biogen Stock Rises Even as Multiple Sclerosis Revenue Tumbles. It Sees Continued Declines in the Portfolio.

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Feb 6, 2026, 6:10 AM EST - 3 months ago

Biogen forecasts annual profit above estimates as Leqembi sales pick up

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Feb 4, 2026, 7:30 AM EST - 3 months ago

Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

Jan 28, 2026, 7:30 AM EST - 3 months ago

Biogen's Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Jan 25, 2026, 6:30 PM EST - 3 months ago

FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease under Priority Review

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Jan 13, 2026, 8:48 AM EST - 4 months ago

Biogen CEO Chris Viehbacher on 2026 drug pipeline outlook, rare disease strategy

Biogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 4:30 PM EST - 4 months ago

Biogen Transcript: 44th Annual J.P. Morgan Healthcare Conference

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Jan 12, 2026, 11:05 AM EST - 4 months ago

Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

Jan 11, 2026, 2:00 PM EST - 4 months ago

Stoke Therapeutics Announces Updates to Timelines for the Completion of Enrollment and a Phase 3 Data Readout from the EMPEROR Study of Zorevunersen for the Treatment of Dravet Syndrome

STOK

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

Jan 5, 2026, 8:00 PM EST - 4 months ago

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Dec 22, 2025, 11:20 AM EST - 4 months ago

The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

Dec 9, 2025, 7:00 AM EST - 5 months ago

Biogen Receives Health Canada Authorization for ZURZUVAE™ (zuranolone), the First and Only Treatment Indicated for Adults with Postpartum Depression in Canada

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Dec 8, 2025, 6:30 PM EST - 5 months ago

“LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 5, 2025, 9:00 AM EST - 5 months ago

Stoke Therapeutics and Biogen Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

STOK

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Dec 5, 2025, 9:00 AM EST - 5 months ago

Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting

Biogen Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 3, 2025, 11:30 AM EST - 5 months ago

Biogen Transcript: Piper Sandler 37th Annual Healthcare Conference

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Dec 2, 2025, 4:40 PM EST - 5 months ago

New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF

Biogen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 2, 2025, 12:55 PM EST - 5 months ago

Biogen Transcript: Evercore ISI 8th Annual HealthCONx Conference

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Biogen and Stoke Therapeutics Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

Dec 1, 2025, 7:30 AM EST - 5 months ago

Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting

STOK

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Nov 27, 2025, 7:30 PM EST - 5 months ago

Eisai Submits New Drug Application for Subcutaneous Formulation of “LEQEMBI®” for the Treatment of Early Alzheimer's Disease in Japan

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Nov 25, 2025, 7:30 AM EST - 5 months ago

Eisai Completes Rolling Submission to US FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Nov 24, 2025, 7:30 AM EST - 5 months ago

Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Nov 24, 2025, 7:30 AM EST - 5 months ago

Versant Ventures Announces Launch of Dayra Therapeutics With Foundational Biogen Partnership

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

Nov 24, 2025, 7:25 AM EST - 5 months ago

Novo Nordisk Stock Falls After Ozempic Fails to Slow Alzheimer's in Trials. Biogen Jumps.

NVO

AI Stocks Are Taking a Beating. What to Buy Instead.

Nov 21, 2025, 1:13 PM EST - 6 months ago

AI Stocks Are Taking a Beating. What to Buy Instead.

AKAM AMZN EXPE LLY

AStrokeOfLuck
AStrokeOfLuck May. 8 at 8:12 AM
$BIIB
0 · Reply
TwongStocks
TwongStocks May. 7 at 6:03 PM
$APLS Equity Corporate Actions Alert #2026 - 310 Information Regarding the Tender Offer of Apellis Pharmaceuticals, Inc. (APLS) https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2026-310 The tender offer by Biogen Inc. $BIIB to acquire all of the outstanding common stock of Apellis Pharmaceuticals, Inc. $APLS is scheduled to expire at 11:59 p.m. ET, on May 13, 2026, unless extended or terminated. The subsequent merger is tentatively scheduled to close prior to the market open on May 14, 2026. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on May 13, 2026. If the merger closes as planned, the stock will remain halted on the day of closing (May 14th) and will be suspended effective May 15, 2026. APLS shareholders will get $41.00 per share plus a non-transferable contingent value right (CVR).
0 · Reply
CapitalMonk
CapitalMonk May. 5 at 3:56 AM
$BIIB Price: $187.21 (+0.08%) Trend: Bullish Market Bias (7D): Sideways ⚖️ Expected Range: ±0.63% RSI: 58.1 | Momentum: Moderate Volume: -49.9% vs avg Volatility: 2.30% Support: $170.43 | Resistance: $195.98 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25
0 · Reply
JFais
JFais Apr. 30 at 7:58 PM
$OMER (L) When they did the zaltenibart deal in October, it gave them a lifeline as no one knew if narsoplimab would get approved in TA-TMA Also, bear commentary= slow launch out of the gate (so far, formulary wins exceeding expectations) I imagine $NVO would love to take Yartemlea into expansion indications (ARDS & other endothelial injury-related disorders), also continue building out its nephrology presence... *Though $BIIB could be another interested party after digesting $APLS
2 · Reply
OMillionaires
OMillionaires Apr. 30 at 10:50 AM
$BIIB PT raised to $260 from $246 at Guggenheim - keeps Buy rating
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 30 at 3:55 AM
$BIIB Share Price: $194.59 Contract Selected: May 22, 2026 $195 Calls Buy Zone: $4.50 – $5.57 Target Zone: $8.02 – $9.80 Potential Upside: 68% ROI Time to Expiration: 22 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
RunnerSignals
RunnerSignals Apr. 29 at 8:10 PM
market warriors $TENB $HUM $CHGG $BIIB $SYRE reversed from red to strong green closes with 6–12% intraday swings and volume 1.2x–1.6x avg
0 · Reply
EarningsLens_ai
EarningsLens_ai Apr. 29 at 1:22 PM
$BIIB blew past estimates but the story underneath is more complicated. Cash flow nearly tripled, which sounds great until you see cost of revenue growing 3x faster than revenue and debt up 38% YoY to $6.29B. Q2 working capital reversal is the thing to watch.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Apr. 29 at 10:16 AM
$BIIB Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $2.17 up 31.52% YoY • Reported revenue of $2.48B up 1.93% YoY • Biogen updated full year 2026 Non-GAAP diluted EPS guidance to $14.25 to $15.25, reflecting an approximately $1.00 impact from acquired IPR&D charges, and expects total revenue to decline by a mid-single digit percentage.
0 · Reply
trichomy
trichomy Apr. 27 at 2:39 PM
$INMB $LEMB $BIIB Let's go InmuneBio!! https://claude.ai/public/artifacts/3dd6649c-e7bf-4f60-9771-28a79622d962 INMB INMB INMB
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Apr. 21 at 3:55 PM
$IONS Zilganersen's commercial success hinges primarily on execution beyond the trial rather than its strong clinical evidence. The real bottleneck isn't payer resistance—it's the diagnostic challenge. Patients frequently misdiagnosed as multiple sclerosis or atypical parkinsonism, getting an accurate diagnosis remains the biggest obstacle to reaching potential patients and driving revenue. $BIIB $SRPT $BMRN #AlexanderDisease Read more: www.clinicaltrialsdaily.com/zilganersen-aso-alexander-disease-pdufa/
0 · Reply
parcha
parcha Apr. 21 at 12:19 PM
Cramer's lightning round $BIIB Biogen: “I read the upgrade today by Wells Fargo, and it talked about a bunch of revenue streams, including Alzheimer’s, and it was very impressive. I actually said, ‘You know what? I got to reopen the file on Biogen.’ It looks pretty darn good.” https://www.cnbc.com/2026/04/20/cramers-lightning-round-buy-aes-corporation.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
parcha
parcha Apr. 21 at 10:49 AM
Lightning Round: Biogen looks pretty darn good, says Jim Cramer $BIIB https://www.cnbc.com/video/2026/04/20/lightning-round-biogen-looks-pretty-darn-good-says-jim-cramer.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
0 · Reply
TangibleOne
TangibleOne Apr. 21 at 1:43 AM
$BIIB Long here and SKM (ticker) for the Anthropic pre IPO exposure!!!! 🤤
0 · Reply
EquityClock
EquityClock Apr. 20 at 7:19 PM
The optimal holding period for Biogen begins today and the break above resistance at the 20-day moving average is providing incremental evidence that the buying demand that is normally realized in the spring is clicking in. Shares of $BIIB have outperformed the market in 14 of the past 20 periods between April 18 and July 26. $IBB
0 · Reply
trichomy
trichomy Apr. 20 at 4:49 PM
$INMB $LEMB $BIIB $INMB
0 · Reply
LandonCapital
LandonCapital Apr. 20 at 12:26 PM
$BIIB https://landoncapital.net/making-a-big-splash-biogen-acquires-tj-biopharmas-felzartamab-for-850m/
0 · Reply
theflynews
theflynews Apr. 20 at 10:11 AM
Wells upgrades Biogen to Overweight on pipeline outside Alzheimer's - $BIIB - https://thefly.com/BIIB
0 · Reply
JFais
JFais Apr. 16 at 1:21 PM
$TVTX- had to rain on the parade didn't you @adamfeuerstein 😉 Good news $TVTX will build out the FSGS market and better treatments will follow (CCR2 blocker DMX-200 & complement inhibitors like $APLS $BIIB Empaveli in P3, BAFF APRIL a la atacicept & $VRTX poveticacicept, etc)
0 · Reply
trichomy
trichomy Apr. 16 at 12:21 PM
$INMB $LEMB $BIIB $INMB
0 · Reply
trichomy
trichomy Apr. 16 at 3:23 AM
$INMB Massive Paradigm Shift in Alzheimer's! The new Cochrane Review (CD016297) just dealt a devastating blow to the anti-amyloid hypothesis. 🚫 Gold-standard data from 42 trials shows that drugs like $LEMB and $BIIB clear plaque but fail to deliver meaningful cognitive benefits, while carrying serious safety risks like brain swelling (ARIA). 🤯 The market narrative is crumbling. Enter $INMB. Their lead asset, XPro™, targets neuroinflammation (soluble TNF), not amyloid. Cochrane's expert recommendation is clear: "Future research... should focus on other treatments." 💡 INmune Bio is the necessary evolution that Cochrane is inadvertently calling for. Structurally de-risked and perfectly positioned with XPro™ moving into pivotal trials with a biomarker-enriched design. Time to look beyond the failed amyloid funnel-vision. Check out my full strategic analysis in the graphic below! 🚀 #Alzheimers #Biotech #Investing #Neuroscience #TheNewNarrative https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD016297/full?highlightAbstract=alzheimer%7Calzheimer%27s%7Calzheim
0 · Reply
Quantumup
Quantumup Apr. 15 at 11:19 AM
Mizuho🏁 $CLYM Outperform; $18 $RHHBY $BIIB VRTX GSK Mizuho said: We are initiating coverage of Climb Bio with an Outperform rating and $18 price target, as we see its lead assets budoprutug (anti-CD19 mAb) and CLYM116 (anti-APRIL mAb) as positioned to establish a compelling B-cell targeting pipeline with best-in-indication profiles in autoimmune nephropathies. Specifically, we believe additional updates for budoprutug in primary membranous nephropathy (pMN) in 2H26 and initial data for CLYM116 in healthy volunteers (HVs) in mid-2026 have the opportunity to provide data points that will validate potential to drive the deepest reductions in proteinuria within their competitive landscapes. As we exit 2026, budoprutug and CLYM116 could be positioned for registrational development across two blockbuster opportunities that we believe could support ~$600M in risk-adjusted WW sales by 2035.
0 · Reply